EMEA-002360-PIP01-18-M02
Key facts
Active substance |
Tirzepatide
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/0174/2022
|
PIP number |
EMEA-002360-PIP01-18-M02
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Eli Lilly and Company Ltd
Email: EU_PAEDIATRIC@LILLY.COM |
Decision type |
PM: decision on the application for modification of an agreed PIP
|